List of Excipients in Branded Drug PAVBLU

PAVBLU Excipient Strategy and Commercial Opportunities in Ophthalmic Biosimilars

Last updated: August 9, 2026

PAVBLU, or aflibercept-ayyh, is an FDA-approved biosimilar to EYLEA (aflibercept) for retinal vascular diseases. Its commercial opportunity is driven less by novel excipient claims than by manufacturing consistency, protein stability, container closure performance, supply reliability, payer contracting, and potential delivery-system extensions. The core formulation is a sterile, preservative-free, single-dose ophthalmic injection containing aflibercept with phosphate buffer, sodium chloride, polysorbate 20, and water for injection.[1,2]

What is PAVBLU and what formulation does it use?

PAVBLU is a recombinant vascular endothelial growth factor inhibitor administered by intravitreal injection. Its reference product is EYLEA, which contains aflibercept at a concentration of 40 mg/mL in a single-dose vial.[1,2]

Attribute	PAVBLU	EYLEA reference product
Active ingredient	Aflibercept-ayyh	Aflibercept
Product type	Biosimilar	Reference biologic
Route	Intravitreal injection	Intravitreal injection
Standard dose	2 mg in 0.05 mL for approved indications	2 mg in 0.05 mL
Concentration	40 mg/mL	40 mg/mL
Preservative	None	None
Primary excipients	Phosphate buffer, sodium chloride, polysorbate 20, water for injection	Phosphate buffer, sodium chloride, polysorbate 20, water for injection
Packaging	Single-dose sterile presentation	Single-dose sterile presentation
Therapeutic areas	Wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion	Same core indications

PAVBLU’s formulation strategy is consistent with the regulatory expectations for a biosimilar: maintain comparable critical quality attributes, including molecular structure, purity, potency, aggregation profile, charge variants, and stability. Excipients can differ in identity or concentration, but any difference must not affect safety, purity, potency, or immunogenicity.[3]

What are the likely functions of PAVBLU excipients?

Excipient	Formulation function	Commercial and technical relevance
Polysorbate 20	Limits protein adsorption and interface-induced aggregation	Controls visible and subvisible particles, but requires management of oxidation and hydrolysis
Sodium phosphate salts	Maintains formulation pH	Affects protein stability, osmolality, and degradation pathways
Sodium chloride	Adjusts tonicity	Supports ocular tolerability and injection comfort
Water for injection	Vehicle	Must meet sterile, endotoxin, and particulate specifications

The formulation is preservative-free because intravitreal products are administered directly into the eye and are generally supplied as single-use presentations. Multidose products containing antimicrobial preservatives would face greater ocular tolerability and regulatory complexity.

How does PAVBLU’s excipient strategy compare with EYLEA?

PAVBLU’s commercial value depends on formulation similarity rather than excipient differentiation. A biosimilar sponsor has limited ability to introduce a materially different excipient system without increasing comparability, immunogenicity, and clinical-development risk.

EYLEA’s formulation is relatively simple compared with many injectable biologics. It does not require a proprietary lipid system, polymer depot, or complex lyophilization platform. This creates a lower-cost manufacturing opportunity, but it also reduces the scope for excipient-based product differentiation.

The most defensible formulation strategy has four elements:

1. Use a well-characterized surfactant system to control protein adsorption.
2. Optimize buffer capacity and pH within the biosimilarity target range.
3. Control subvisible particles and aggregates during filling, transport, and injection.
4. Maintain a preservative-free, single-dose presentation that matches ophthalmic practice.

The key technical risk is polysorbate degradation. Polysorbate 20 can undergo hydrolysis and oxidation, potentially generating free fatty acids, peroxide species, particles, and protein degradation products. A sponsor therefore needs tight control over raw-material variability, peroxide levels, oxygen exposure, light exposure, and storage conditions.

What commercial opportunities exist for PAVBLU excipients?

The highest-value opportunities are indirect. Excipient suppliers and contract manufacturers can create commercial value through supply security, quality control, and formulation-performance services rather than through a new excipient claim.

High-purity polysorbate 20 supply

Polysorbate 20 is a critical excipient because its degradation can affect particle formation and protein stability. Opportunities include:

• Low-peroxide polysorbate 20 grades
• Tighter control of fatty-acid distribution
• Improved lot-to-lot consistency
• Oxidation-resistant packaging
• Supply agreements with dual manufacturing sites
• Analytical methods for peroxide, free fatty acids, and degradation products

A supplier able to provide reliable pharmaceutical-grade polysorbate 20 with documented control of oxidative impurities may obtain a preferred-vendor position with biosimilar manufacturers.

Excipient characterization and release testing

PAVBLU manufacturers require more than pharmacopeial identity testing. High-value services include:

• Polysorbate degradation testing
• Particle characterization
• Protein aggregation analysis
• Extractables and leachables testing
• Container closure integrity testing
• Compatibility studies with syringes, needles, and vial components
• Stability-indicating methods
• Forced-degradation studies

This testing is commercially relevant because injectable biologics can fail during filling, shipping, or administration even when the bulk drug substance meets release specifications.

Low-binding primary packaging

Aflibercept can adsorb to container and device surfaces. Vial and syringe materials therefore affect delivered dose and product quality. Commercial opportunities include:

• Low-binding glass or polymer containers
• Silicone-oil-reduced syringes
• Tungsten-controlled glass systems
• Low-shedding elastomer closures
• Prefilled syringe systems designed for ophthalmic injection
• Container systems with validated protein recovery

Packaging changes may provide greater commercial differentiation than changes to the excipient composition.

What formulations are protected by PAVBLU or EYLEA patents?

Aflibercept patent protection is concentrated in biologic composition, formulation, manufacturing, dosing, and therapeutic-use claims. The reference product’s patent estate does not necessarily give PAVBLU exclusivity over each excipient individually.

Protection category	Relevance to PAVBLU
Aflibercept protein and variants	Defines the biologic molecule and related constructs
Pharmaceutical compositions	May cover concentration, buffer, tonicity agents, surfactants, and stability ranges
Treatment methods	Covers retinal disease indications and dosing schedules
Manufacturing methods	May cover cell culture, purification, formulation, or filling processes
High-dose aflibercept formulations	Relevant to 8 mg products and potential future extensions
Delivery devices	May cover prefilled syringes or administration systems

For biologics, patent analysis must be separated from FDA exclusivity. PAVBLU is governed by the Biologics Price Competition and Innovation Act pathway, and its relevant patent information is generally assessed through the Purple Book and litigation records rather than the Orange Book.[3,4]

The commercial implication is that an excipient formulation may be technically noninfringing but still commercially constrained by patents covering the active ingredient, method of treatment, concentration, or manufacturing process.

When does PAVBLU lose exclusivity?

PAVBLU does not receive an independent small-molecule-style five-year new chemical entity exclusivity period. Biosimilar products receive regulatory exclusivity based on the reference biologic’s exclusivity history and the applicable BPCIA framework.

PAVBLU’s market protection is therefore determined by:

• The reference product’s biologic exclusivity history
• Aflibercept composition and formulation patents
• Method-of-use patents
• Patent litigation and settlement terms
• Any pediatric-exclusivity extensions
• PAVBLU-specific patents covering its manufacturing process or presentation

The reference product EYLEA received FDA approval in 2011. Its regulatory exclusivity period has expired, allowing biosimilar approvals. Patent barriers, rather than statutory biologic exclusivity, remain the principal timing issue for commercial entry.[2,4]

What is the FDA regulatory status of PAVBLU?

PAVBLU is an FDA-approved biosimilar to EYLEA. Its approval establishes that the product is highly similar to the reference product and has no clinically meaningful differences in safety, purity, and potency for the approved conditions of use.[1,3]

The approval does not automatically establish interchangeability. Interchangeability is a separate designation requiring additional evidence under FDA standards. Pharmacy-level substitution rules depend on state law and the product’s FDA labeling status.

Does PAVBLU have interchangeable status?

Interchangeability should be evaluated separately from biosimilarity. A product may be biosimilar without being interchangeable. The commercial consequences include:

• Greater need for physician-led switching
• More importance for retinal-specialty contracting
• Potentially slower conversion from EYLEA
• Greater reliance on lower acquisition cost
• Increased value of real-world evidence and treatment-continuity data

How strong is PAVBLU’s patent estate?

PAVBLU’s own patent strength is likely less important than its ability to operate around the EYLEA estate. The principal risk areas are:

1. Aflibercept composition claims.
2. Formulation claims covering concentration, pH, buffer, and surfactant combinations.
3. Dosing and treatment claims for retinal indications.
4. Manufacturing claims covering purification or formulation.
5. Device and presentation claims.
6. High-dose aflibercept claims associated with EYLEA HD.

A biosimilar’s excipient strategy should be designed with a freedom-to-operate analysis that separates:

• Active-ingredient claims
• Formulation claims
• Process claims
• Presentation claims
• Method-of-use claims

An excipient substitution may avoid one formulation claim while creating a new comparability burden. The lowest-risk route is usually a formulation that remains close to the reference product while avoiding unnecessary dependence on a specifically claimed parameter.

What generic or biosimilar launch risks exist for PAVBLU?

PAVBLU faces biosimilar, not generic, launch risks. The main risks are commercial and operational.

Risk	Impact on PAVBLU
Physician reluctance to switch	Slows conversion from EYLEA
Payer preference for lower-cost products	Supports adoption but can compress net price
Limited interchangeability	Reduces automatic substitution
Retina-clinic inventory complexity	Increases implementation burden
Cold-chain failures	Can cause product loss and quality concerns
Polysorbate degradation	Can increase particles and aggregate risk
Device compatibility issues	May affect dose delivery and clinician preference
Settlement restrictions	Can alter launch timing
Competing aflibercept biosimilars	Increases rebate and contracting pressure

The use of the same basic excipient architecture as EYLEA can reduce clinician concern and simplify analytical comparability. It can also limit product differentiation when multiple aflibercept biosimilars enter the market.

Which companies are challenging the EYLEA franchise?

The aflibercept competitive landscape includes the reference product, biosimilar manufacturers, and products using alternative dose strengths or delivery formats.

Product or program	Company or sponsor	Competitive position
EYLEA	Regeneron and Bayer	Reference aflibercept product
EYLEA HD	Regeneron and Bayer	Higher-dose, longer-interval formulation
PAVBLU	Amgen	FDA-approved aflibercept biosimilar
Other aflibercept biosimilars	Multiple developers	Price competition and contracting pressure
Ranibizumab biosimilars	Multiple sponsors	Compete in retinal vascular disease
Faricimab	Roche	Alternative mechanism and dosing interval
Brolucizumab	Novartis	Alternative anti-VEGF option
Bevacizumab compounded use	Compounding pharmacies	Low-cost off-label alternative

PAVBLU’s most direct competitive threat is not a new excipient platform. It is the combination of other aflibercept biosimilars, EYLEA HD, and payer-driven product selection.

What licensing deals and settlement agreements affect PAVBLU?

Biosimilar commercialization can depend on confidential or partially disclosed patent settlements. These agreements may specify:

• Earliest permitted launch date
• Geographic launch rights
• Royalty obligations
• Restrictions on formulation or device variants
• Treatment of future high-dose products
• Manufacturing or supply arrangements

A settlement may permit market entry before the last listed patent expires while preserving the reference sponsor’s rights against particular presentations or uses. Commercial diligence should therefore analyze court dockets, FDA approval records, patent assignments, and public company disclosures together.

No Orange Book listing governs PAVBLU because it is a biologic. The relevant records are the FDA Purple Book, BPCIA patent-exchange materials where available, and federal patent litigation filings.[3,4]

What manufacturing and IP barriers affect PAVBLU excipients?

The principal manufacturing barriers are process control and sterile-product reliability.

Bulk drug substance and formulation

Aflibercept is a complex recombinant fusion protein. Commercial manufacturing requires control of:

• Cell-line consistency
• Glycosylation
• Aggregation
• Charge variants
• Host-cell proteins
• Residual DNA
• Viral clearance
• Concentration and fill accuracy

The formulation process must prevent stress from mixing, pumping, filtration, hold times, and filling. Surfactant addition order and shear exposure can affect product quality.

Sterile fill-finish

Intravitreal products have narrow tolerance for particles and visible defects. Commercial barriers include:

• Sterile filtration validation
• Aseptic filling
• Low-volume fill accuracy
• Container closure integrity
• Vial and stopper compatibility
• Shipping qualification
• Particulate control

These barriers create opportunities for contract development and manufacturing organizations with experience in ophthalmic biologics.

How does PAVBLU compare with alternative commercial strategies?

Strategy	Development burden	Differentiation	Commercial potential
Reference-like vial formulation	Low to moderate	Low	Fastest biosimilar adoption path
Prefilled syringe	Moderate	Moderate	Better clinic workflow and reduced preparation
Low-volume concentrated dose	High	High	Potentially lower injection burden, but comparability risk
High-dose formulation	Very high	High	Longer dosing intervals, but substantial clinical and patent exposure
New surfactant system	Moderate to high	Moderate	Possible stability benefit; higher regulatory risk
Lyophilized product	High	Moderate	Longer stability potential; adds reconstitution burden
Sustained-release delivery	Very high	High	New product category with substantial clinical and IP requirements

The strongest near-term opportunity is a reliable, low-cost, preservative-free presentation with strong cold-chain performance. A prefilled syringe could offer more differentiation than a new excipient system while remaining commercially aligned with ophthalmology workflow.

What revenue exposure does PAVBLU create?

PAVBLU targets a large retinal-treatment market in which anti-VEGF drugs generate substantial pharmaceutical spending. Revenue exposure is determined by:

• Share captured from EYLEA
• Payer formulary placement
• Price discount versus EYLEA
• Physician switching behavior
• Availability of EYLEA HD
• Number of competing aflibercept biosimilars
• Distribution through specialty pharmacies and physician practices
• Reimbursement under buy-and-bill channels

The product’s excipient composition will rarely determine revenue directly. It affects revenue through product quality, supply continuity, injection-site tolerability, storage performance, and the ability to support a differentiated presentation.

Key Takeaways

• PAVBLU is an aflibercept biosimilar using a conventional preservative-free ophthalmic formulation.
• The core excipients are phosphate buffer, sodium chloride, polysorbate 20, and water for injection.
• Polysorbate 20 quality, oxidative stability, and particle control are the most important excipient issues.
• The strongest commercial opportunity is supply reliability and formulation-performance control, not a novel excipient claim.
• Prefilled syringes and optimized container systems offer more practical differentiation than major formulation changes.
• PAVBLU’s market access depends on BPCIA patent strategy, payer contracting, physician adoption, and competition from other aflibercept biosimilars.
• The Orange Book is not the governing patent reference. The Purple Book and federal patent records are more relevant.
• EYLEA HD creates a major competitive constraint because it competes through dosing convenience rather than price alone.
• A reference-like formulation lowers comparability risk but limits differentiation.
• A new excipient system could create stability benefits but would increase regulatory and intellectual-property exposure.

FAQs About PAVBLU Excipient and Commercial Strategy

Is PAVBLU preservative-free?

Yes. PAVBLU is supplied as a sterile, single-dose intravitreal product without an antimicrobial preservative.[1]

Does PAVBLU use polysorbate 20?

Yes. Polysorbate 20 is used as a protein-stabilizing surfactant in the formulation.[1]

Can PAVBLU be reformulated with polysorbate 80?

Potentially, but a switch to polysorbate 80 would require extensive analytical and regulatory comparability work. The change could affect protein stability, particles, immunogenicity risk, and container compatibility.

Is PAVBLU protected by Orange Book patents?

No. PAVBLU is a biologic. Patent and exclusivity analysis should use the FDA Purple Book, BPCIA records, patent assignments, and litigation filings rather than relying on Orange Book listings.

Could PAVBLU be developed in a prefilled syringe?

A prefilled syringe is a plausible lifecycle-management opportunity, but it would require device compatibility, extractables and leachables, container closure, dose-delivery, stability, and usability validation.

References

1. U.S. Food and Drug Administration. (2025). PAVBLU (aflibercept-ayyh) prescribing information.
2. U.S. Food and Drug Administration. (2023). EYLEA (aflibercept) injection prescribing information.
3. U.S. Food and Drug Administration. (2021). Development of therapeutic protein biosimilars: Comparative analytical assessment and other quality-related considerations. Guidance for Industry.
4. U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products.